Thatiana L Assis de Brito1, Andréa Monte-Alto-Costa1, Bruna Romana-Souza2. 1. Department of Histology and Embryology, State University of Rio de Janeiro, Rio de Janeiro, Brazil. 2. Department of Histology and Embryology, State University of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: romanabio@yahoo.com.br.
Abstract
AIMS: β-Adrenoceptors modulate acute wound healing; however, few studies have shown the effects of β-adrenoceptor blockade on chronic wounds. Therefore, this study investigated the effect of β1-/β2-adrenoceptor blockade in wound healing of pressure ulcers. MAIN METHODS: Male mice were daily treated with propranolol (β1-/β2-adrenoceptor antagonist) until euthanasia. One day after the beginning of treatment, two cycles of ischemia-reperfusion by external application of two magnetic plates were performed in skin to induce pressure ulcer formation. KEY FINDINGS: Propranolol administration reduced keratinocyte migration, transforming growth factor-β protein expression, re-epithelialization, and necrotic tissue loss. Neutrophil number and neutrophil elastase protein expression were increased in propranolol-treated group when compared with control group. Propranolol administration delayed macrophage mobilization and metalloproteinase-12 protein expression and reduced monocyte chemoattractant protein-1 protein expression. Myofibroblastic differentiation, angiogenesis, and wound closure were delayed in the propranolol-treated animals. Propranolol administration increased neo-epidermis thickness, reduced collagen deposition, and enhanced tenascin-C expression resulting in the formation of an immature and disorganized collagenous scar. SIGNIFICANCE: β1-/β2-Adrenoceptor blockade delays wound healing of ischemia-reperfusion skin injury through the impairment of the re-epithelialization and necrotic tissue loss which compromise wound inflammation, dermal reconstruction, and scar formation.
AIMS: β-Adrenoceptors modulate acute wound healing; however, few studies have shown the effects of β-adrenoceptor blockade on chronic wounds. Therefore, this study investigated the effect of β1-/β2-adrenoceptor blockade in wound healing of pressure ulcers. MAIN METHODS: Male mice were daily treated with propranolol (β1-/β2-adrenoceptor antagonist) until euthanasia. One day after the beginning of treatment, two cycles of ischemia-reperfusion by external application of two magnetic plates were performed in skin to induce pressure ulcer formation. KEY FINDINGS:Propranolol administration reduced keratinocyte migration, transforming growth factor-β protein expression, re-epithelialization, and necrotic tissue loss. Neutrophil number and neutrophil elastase protein expression were increased in propranolol-treated group when compared with control group. Propranolol administration delayed macrophage mobilization and metalloproteinase-12 protein expression and reduced monocyte chemoattractant protein-1 protein expression. Myofibroblastic differentiation, angiogenesis, and wound closure were delayed in the propranolol-treated animals. Propranolol administration increased neo-epidermis thickness, reduced collagen deposition, and enhanced tenascin-C expression resulting in the formation of an immature and disorganized collagenous scar. SIGNIFICANCE: β1-/β2-Adrenoceptor blockade delays wound healing of ischemia-reperfusion skin injury through the impairment of the re-epithelialization and necrotic tissue loss which compromise wound inflammation, dermal reconstruction, and scar formation.
Authors: Andrezza Maria Côrtes Thomé Lima; Luiz Philippe da Silva Sergio; Larissa Alexsandra da Silva Neto Trajano; Bianca Paschoal de Souza; João Pedro da Motta Mendes; Adriano Fonseca Ribeiro Cardoso; Caroline Pisa Figueira; Beatriz Dos Anjos Tavares; Daniella Sousa Figueira; André Luiz Mencalha; Eduardo Tavares Lima Trajano; Adenilson de Souza da Fonseca Journal: Lasers Med Sci Date: 2019-08-31 Impact factor: 3.161
Authors: Mariáurea Matias Sarandy; Rômulo Dias Novaes; Sérgio Luiz Pinto da Matta; Jose Mario da Silveira Mezencio; Marcelo Barreto da Silva; José Cola Zanuncio; Reggiani Vilela Gonçalves Journal: Evid Based Complement Alternat Med Date: 2015-06-11 Impact factor: 2.629
Authors: Marco A Pires-Lapa; Claudia E Carvalho-Sousa; Erika Cecon; Pedro A Fernandes; Regina P Markus Journal: Int J Mol Sci Date: 2018-07-26 Impact factor: 5.923